Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
171.70
+4.35 (2.60%)
Oct 6, 2025, 11:11 AM EDT - Market open
Natera Revenue
Natera had revenue of $546.60M in the quarter ending June 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $1.96B, up 44.38% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.96B
Revenue Growth
+44.38%
P/S Ratio
11.21
Revenue / Employee
$442,997
Employees
4,434
Market Cap
23.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTRA News
- 5 days ago - Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT - Business Wire
- 6 days ago - Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer - Business Wire
- 7 days ago - Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Business Wire
- 12 days ago - Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Can Natera Stock Reach $500? - Forbes
- 25 days ago - Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability - Seeking Alpha
- 5 weeks ago - Natera Provides Update on Patent Litigation with NeoGenomics - Business Wire